A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell Function

A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell Function
Condition:   New-onset type1 Diabetes
Interventions:   Drug: Ladarixin;   Drug: Placebo
Sponsor:   Dompé Farmaceutici S.p.A
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 7, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments